Silence Therapeutics plc Other Comprehensive Income (Loss), Net of Tax
Silence Therapeutics plc (SLN) reported Other Comprehensive Income (Loss), Net of Tax of $27.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-10
- Silence Therapeutics plc other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was $27.00K, a 99.60% decline year-over-year.
- Silence Therapeutics plc other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$392.00K, a 110.61% decline year-over-year.
- Silence Therapeutics plc other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was $97.00K.
- Silence Therapeutics plc other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was -$1.67M, a 121.75% decline year-over-year.
- Silence Therapeutics plc other comprehensive income (loss), net of tax for fiscal 2025 was $8.80M.
- Silence Therapeutics plc other comprehensive income (loss), net of tax for fiscal 2024 was -$1.05M, a 233.71% decline from fiscal 2023.
- Silence Therapeutics plc other comprehensive income (loss), net of tax for fiscal 2023 was $789.00K.
- Silence Therapeutics plc other comprehensive income (loss), net of tax for fiscal 2022 was -$86.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $27.00K 10-Q · filed 2026-08-10 | -$365.00K 10-Q · filed 2026-08-10 | -$268.00K derived: sum of 3 quarters · filed 2026-08-10 | -$1.94M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$392.00K 10-Q · filed 2026-05-07 | -$295.00K derived: sum of 2 quarters · filed 2026-05-07 | -$1.96M derived: sum of 3 quarters · filed 2026-05-07 | $4.72M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $97.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$1.57M derived: sum of 2 quarters · filed 2026-03-05 | $5.11M derived: sum of 3 quarters · filed 2026-08-10 | $8.80M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$1.67M 10-Q · filed 2025-11-06 | $5.01M derived: sum of 2 quarters · filed 2026-08-10 | $8.71M 10-Q · filed 2025-11-06 | -$152.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $6.68M 10-Q · filed 2026-08-10 | $10.38M 10-Q · filed 2026-08-10 | $1.52M derived: sum of 3 quarters · filed 2026-08-10 | $9.19M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $3.70M 10-Q · filed 2026-05-07 | -$5.16M derived: sum of 2 quarters · filed 2026-05-07 | $2.51M derived: sum of 3 quarters · filed 2026-05-07 | $2.70M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$8.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$1.19M derived: sum of 2 quarters · filed 2026-03-05 | -$999.00K derived: sum of 3 quarters · filed 2026-03-05 | -$1.05M 10-K · filed 2026-03-05 |
| 2024-09-30 | $7.67M 10-Q · filed 2025-11-06 | $7.86M derived: sum of 2 quarters · filed 2025-11-06 | $7.80M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $186.00K 10-Q · filed 2025-08-07 | $129.00K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$57.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $789.00K 10-K · filed 2025-02-27 | |||
| 2022-12-31 | -$86.00K 10-K · filed 2025-02-27 |